Analysis of drug interactions at the end of life

BMJ Supportive and Palliative Care

Volumn 5, Issue 3, 2015, Pages 281-286

  Morgan, N A ^a   Rowett, D ^b   Currow, D C ^a,c  

^a MODBURY HOSPITAL   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AUSTRALIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG INTERACTION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PALLIATIVE THERAPY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TERMINAL CARE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOFTWARE; TERMINAL CARE;

EID: 84939808969     PISSN: 2045435X     EISSN: 20454368     Source Type: Journal    
DOI: 10.1136/bmjspcare-2014-000767     Document Type: Article

References (39)

1. Riechelmann RP, Krzyzanowska MK, O'Carroll A, et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 2007;15:1407-12.
2. Agar M, Currow D, Plummer J, et al. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 2009;23:257-65.
3. Currow D, Stevenson J, Abernethy AP, et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007;55:590-5.
4. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65years or older. Arch Intern Med 2010;170:1142-8.
5. Obreli Neto PR, Nobili A, de Lyra DP Jr, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. J Pharm Pharmaceut Sci 2012;15:332-43.
6. Russell BJ, Rowett D, Abernethy AP, et al. Prescribing for comorbid disease in a palliative population: focus on the use of lipid-lowering medications. Intern Med J 2014;44:177-84.
7. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000;18:1780-99.
8. Frechen S, Zoeller A, Ruberg K, et al. Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 2012;35:745-58.
9. Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008;35:535-43.
10. Miller GC, Britt HC, Valenti L. Adverse drug events in general practice patients in Australia. Med J Aust 2006;184:321-4.
11. Miller GC, Valenti L, Britt H, et al. Drugs causing adverse events in patients aged 45 or older: a randomised survey of Australian general practice patients. BMJ Open 2013;3: e003701.
12. Davidson KW, Kahn A, Price RD. Reduction of adverse drug interactions by computerized drug interaction screening. J Fam Pract 1987;25:371-5.
13. Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort. Prevalence and relevance. Drugs Aging 2008;25:343-55.
14. Glintborg B, Andersen SE, DalhoffK. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 2005;61:675-81.
15. Phillips AL, Nigro O, Macolino KA, et al. Hospital admissions caused by adverse drug events: an Australian prospective study. Aust Health Rev 2014;38:51-7.
16. Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56:286-90.
17. Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009;20:1907-12.
18. Miranda V, Fede A, Nobuo M, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Symptom Manage 2011;42:342-53.
19. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
20. Dechanont S, Mapharta S, Butthum B, et al. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2014;23:489-97.
21. White C, McCann MA, Jackson N. First do no harm terminal restlessness or drug-induced delirium. J Palliat Med 2007;10:345-51.
22. Zimmerman KM, Salow M, Skarf LM, et al. Increasing anticholinergic burden and delirium in palliative care inpatients. Palliat Med 2014;28:335-41.
23. Gaertner J, Ruberg K, Schlesiger G, et al. Drug interactions in palliative care-it's more than cytochrome P450. Palliat Med 2012;26:813-25.
24. Stockley's Drug Interactions on-line 10th edition. http://www. medicinescomplete.com/(accessed 12 Apr 2014).
25. Abernethy AP, Shelby-James T, Fazekas BS, et al. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliat Care 2005;4:7.
26. Hillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 2010;28:3002-7.
27. De Smedt RH, Denig P, Haaijer-Ruskamp FM, et al. Perceived medication adverse effects and coping strategies reported by chronic heart failure patients. Int J Clin Pract 2009;63:233-42.
28. Lampela P, Hartikainen S, Sulkava R, et al. Adverse drug effects in elderly people-a disparity between clinical examination and adverse effects self-reported by the patient. Eur J Clin Pharmacol 2007;63:509-15.
29. De Smedt RH, Jaarsma T, Haaijer-Ruskamp FM, et al. The impact of perceived adverse effects on medication changes in heart failure patients. J Cardiac Failure 2010;16:135-41.
30. Forster AJ, MurffHJ, Peterson JF, et al. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005;20:317-23.
31. Mercadante S, Fulfaro F, Casuccio A. Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 2001;17:37-40.
32. Twycross RG, Bergl S, John S, et al. Monitoring drug use in palliative care. Palliat Med 1994;8:137-43.
33. Magee C. The use of herbal and other dietary supplements and the potential for drug interactions in palliative care. Palliat Med 2007;21:547-8.
34. Weingart SN, Gandhi TK, Seger AC, et al. Patient reported mediation symptoms in primary care. Arch Intern Med 2005;165:234-40.
35. Ahearn MD, Kerr SJ. General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software. MJA 2003;179:34-7.
36. Phansalkar S, Desai A, Choksi A, et al. Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records. BMC Med Inform Decis Mak 2013;13:65.
37. Weingart SN, Seger AC, Feola N, et al. Electronic drug interaction alerts in ambulatory care. Drug Saf 2011;34:587-93.
38. Regnard C, Hunter A. Increasing prescriber awareness of drug interactions in palliative care. J Pain Symptom Manage 2005;29:219-21.
39. Wilson S, Wahler R, Brown J, et al. Impact of pharmacist intervention on clinical outcomes in the palliative care setting. Am J Hosp Palliat Care 2011;28:316-20.